SAN

81.07

-1%↓

UCB

247.5

-3.58%↓

SHL.DE

38.15

-0.24%↓

ARGX

686.4

-3%↓

VIE

35.3

-0.45%↓

SAN

81.07

-1%↓

UCB

247.5

-3.58%↓

SHL.DE

38.15

-0.24%↓

ARGX

686.4

-3%↓

VIE

35.3

-0.45%↓

SAN

81.07

-1%↓

UCB

247.5

-3.58%↓

SHL.DE

38.15

-0.24%↓

ARGX

686.4

-3%↓

VIE

35.3

-0.45%↓

SAN

81.07

-1%↓

UCB

247.5

-3.58%↓

SHL.DE

38.15

-0.24%↓

ARGX

686.4

-3%↓

VIE

35.3

-0.45%↓

SAN

81.07

-1%↓

UCB

247.5

-3.58%↓

SHL.DE

38.15

-0.24%↓

ARGX

686.4

-3%↓

VIE

35.3

-0.45%↓

Search

Laboratorios Farmaceuticos Rovi SA

Fechado

SetorSaúde

85.4 0.06

Visão Geral

Variação de preço das ações

24h

Atual

Mín

85

Máximo

86.65

Indicadores-chave

By Trading Economics

Rendimento

-33M

43M

Vendas

7.9M

218M

P/E

Médio do Setor

35.869

63.808

EPS

0.834

Margem de lucro

19.539

Funcionários

1,950

EBITDA

-21M

63M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+1.94% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

353M

4.3B

Abertura anterior

85.34

Fecho anterior

85.4

Sentimento de Notícias

By Acuity

50%

50%

159 / 348 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bullish Evidence

Laboratorios Farmaceuticos Rovi SA Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

20 de abr. de 2026, 23:49 UTC

Notícias Principais

New Zealand 1Q Inflation Higher Than Expected

20 de abr. de 2026, 23:10 UTC

Ações em Alta

Stocks to Watch: Amazon, Alaska Air Group, BridgeBio Oncology, AXT

20 de abr. de 2026, 22:53 UTC

Grandes Movimentos do Mercado

BridgeBio Oncology Shares Rise After FDA Fast-Tracks Pancreatic Cancer Treatment

20 de abr. de 2026, 23:45 UTC

Conversa de Mercado

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

20 de abr. de 2026, 23:44 UTC

Conversa de Mercado

Gold Consolidates as End of Cease-Fire Looms -- Market Talk

20 de abr. de 2026, 23:39 UTC

Conversa de Mercado

Rio Tinto Posts Strong Start to Year -- Market Talk

20 de abr. de 2026, 23:30 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

20 de abr. de 2026, 23:30 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

20 de abr. de 2026, 23:30 UTC

Conversa de Mercado

Super Retail's Earnings Outlook Less Rosy -- Market Talk

20 de abr. de 2026, 23:09 UTC

Conversa de Mercado

Viva Energy's Refinery Fire More Benign Than Jefferies Thought -- Market Talk

20 de abr. de 2026, 22:31 UTC

Aquisições, Fusões, Aquisições de Empresas

Anthropic, Amazon Tighten Bond in $5 Billion Investment and Computing Deal -- WSJ

20 de abr. de 2026, 22:26 UTC

Aquisições, Fusões, Aquisições de Empresas

West African Resources Says Sanbrado, Toega Operations Not Subject to Govt Request for Additional Participation

20 de abr. de 2026, 22:25 UTC

Aquisições, Fusões, Aquisições de Empresas

West African Resources Plans to Distribute Cash Proceeds to Shareholders Via Special Dividend

20 de abr. de 2026, 22:25 UTC

Aquisições, Fusões, Aquisições de Empresas

West African Resources Aims for Acquisition to Be Completed by End-2026

20 de abr. de 2026, 22:25 UTC

Aquisições, Fusões, Aquisições de Empresas

West African Resources Says to Work Cooperatively With Govt to Finalize Deal Terms

20 de abr. de 2026, 22:25 UTC

Aquisições, Fusões, Aquisições de Empresas

West African Resources Says Acquisition Would Be for A$175 Million

20 de abr. de 2026, 22:24 UTC

Aquisições, Fusões, Aquisições de Empresas

West African Resources Says Burkina Faso Govt Issues Decree to Acquire 25% of Kiaka

20 de abr. de 2026, 22:15 UTC

Aquisições, Fusões, Aquisições de Empresas

Anthropic, Amazon Tighten Bond in $5 Billion Investment and Computing Deal -- WSJ

20 de abr. de 2026, 22:01 UTC

Aquisições, Fusões, Aquisições de Empresas

Amazon Invests $5B in Anthropic Amid Expanded Collaboration

20 de abr. de 2026, 21:38 UTC

Conversa de Mercado

Apple's New CEO Will Face Immediate Pressure on AI Strategy -- Market Talk

20 de abr. de 2026, 21:33 UTC

Aquisições, Fusões, Aquisições de Empresas

Uber Expands Stake In Lucid for Robo-Taxis. This Is How Tesla's Stock Is Responding. -- Barrons.com

20 de abr. de 2026, 21:24 UTC

Conversa de Mercado

Apple's CEO Change Timing Will Garner Mixed Reaction, Analyst Says -- Market Talk

20 de abr. de 2026, 21:24 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

20 de abr. de 2026, 21:13 UTC

Ganhos

Alaska Air: Expansion of Card Portfolio Expected to Accelerate Loyalty Platform Beyond Incremental $150M Profit Outlined in Alaska Accelerate Strategy

20 de abr. de 2026, 21:10 UTC

Ganhos

Alaska Air to Move Toward a Single Issuer for Atmos Rewards Credit Cards

20 de abr. de 2026, 21:09 UTC

Ganhos

Alaska Air Sees 2Q Capacity Up About 1% Year-Over-Year, Down Nearly a Point From Original Views, on 'Proactive Trimming' of May and June Capacity

20 de abr. de 2026, 21:08 UTC

Ganhos

Alaska Air 'Continues to Operate From a Position of Strength,' With Healthy Balance Sheet, Strong Liquidity, About $20B in Unencumbered Assets

20 de abr. de 2026, 21:07 UTC

Ganhos

Alaska Air: Taken Together, Rev, Cost and Fuel Assumptions Result in 2Q Adjusted Loss Per Share Estimate of About $1

20 de abr. de 2026, 21:05 UTC

Ganhos

Alaska Air: This Assumption Adds About $600M of Expense to 2Q, Equivalent to EPS Headwind of $3.60

20 de abr. de 2026, 21:05 UTC

Ganhos

Alaska Air Expects 2Q Fuel Cost to Average About $4.50 Based on Forward Curve Today

Comparação entre Pares

Variação de preço

Laboratorios Farmaceuticos Rovi SA Previsão

Preço-alvo

By TipRanks

1.94% parte superior

Previsão para 12 meses

Média 86.75 EUR  1.94%

Máximo 90 EUR

Mínimo 83.5 EUR

Com base em 2 analistas de Wall Street que oferecem metas de preço de 12 meses para Laboratorios Farmaceuticos Rovi SA - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

2 ratings

1

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

51.1 / N/ASuporte e Resistência

Curto Prazo

Weak Bullish Evidence

Médio Prazo

Strong Bullish Evidence

Longo Prazo

Weak Bearish Evidence

Sentimento

By Acuity

159 / 348 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.
help-icon Live chat